Price targets

Analyst ratings

7 analysts rated this company in the past 90 days. The average target price is €57.86, this is a change of +19.8% compared to the current price.

• September 25, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Buy" rating on Siemens Healthineers with a price target of €60. The final quarter results, due on November 5, should allow the medical technology group to achieve its raised targets for the fiscal year, Julien Dormois wrote in an outlook published Thursday. Repeated statements about impending headwinds point to risks for the 2025/26 earnings (EPS) estimates. However, the new fiscal year could mark a transitional year and lay the foundation for ambitious new plans for the following years./rob/gl/men

  Publication of the original study: September 25, 2025 / 3:06 p.m. / Time zone not specified in the study. First distribution of the original study: September 25, 2025 / 3:06 p.m. / Time zone not specified in the study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 24, 2025

  Berenberg maintains Siemens Healthineers 'Buy' rating - target €57

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Siemens Healthineers with a price target of €57. The Bavarian company has the current challenges well under control, wrote Sam England after the third day of the Berenberg conference on Wednesday./ag/mf

  Publication of the original study: September 24, 2025 / 3:51 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 17, 2025

  Berenberg maintains Siemens Healthineers 'Buy' rating - target €57

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Siemens Healthineers with a price target of €57. The medical technology group has experienced a frustrating 2025 so far, wrote Sam England in a study released Thursday. Operational progress is being overshadowed by exogenous factors such as tariffs, the China business, and a potential stake sale by parent company Siemens. However, England also sees structural and product-related drivers that are likely to favor medium-term growth./edh/tav

  Publication of the original study: September 17, 2025 / 4:58 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 10, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - Following a report in the media regarding a potential sale of the diagnostics division, analyst Jefferies has maintained its rating for Siemens Healthineers at "Buy" with a price target of €60. The proposed sale price appears to adequately reflect the division's mixed business performance, wrote Julien Dormois in a report released Wednesday. The analyst generally takes a positive view of the medical technology group. Price drivers are imminent./rob/mis/nas

  Publication of the original study: September 10, 2025 / 3:44 PM / Time zone not specified in the study

  First distribution of the original study: September 10, 2025 / 3:44 PM / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 3, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained its rating for Siemens Healthineers at "Buy" with a price target of 60 euros. At the Siemens subsidiary, all eyes are on the capital markets day in November and the parent company's plans for its shares, Julien Dormois wrote Wednesday evening after a healthcare conference with representatives from Siemens Health, Sonova, and Smith & Nephew./ag/gl

  Publication of the original study: September 3, 2025 / 5:15 p.m. / ET First distribution of the original study: September 3, 2025 / 7:01 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 19, 2025

  UBS leaves Siemens Healthineers at 'Neutral' - Target 50 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €50. Graham Doyle adjusted his valuation model in his review published Wednesday to reflect the third-quarter results. He considers market expectations for adjusted operating results through 2029 to be up to 6 percent too high. However, the stock valuation is roughly appropriate./rob/ag/gl

  Publication of the original study: August 19, 2025 / 3:58 p.m. / GMT First distribution of the original study: August 20, 2025 / Time not specified in the study / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 31, 2025

  Deutsche Bank maintains 'Buy' rating on Siemens Healthineers

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Siemens Healthineers with a price target of €62. Analyst Falko Friedrichs remains bullish on the healthcare technology provider's shares in a study released Thursday following the company's third-quarter results. However, he acknowledges that uncertainty remains regarding what will happen to the remaining shares of Siemens AG. He understands investors' frustration in this regard. There will likely be no clarity until the Capital Markets Day in December./tih/ajx

  Publication of the original study: July 31, 2025 / Time not specified in the study / CET

  First distribution of the original study: July 31, 2025 / 8:02 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 30, 2025

  Berenberg maintains Siemens Healthineers 'Buy' rating - target €57

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Siemens Healthineers following the company's earnings release, with a price target of €57. Analyst Sam England, in a study released Wednesday, attested that the medical technology manufacturer showed good momentum in the third fiscal quarter, exceeding expectations in both revenue and earnings. The ratio of incoming orders to invoiced revenue (book-to-bill) is also solid./tih/la

  Publication of the original study: July 30, 2025 / 9:46 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 30, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained its "Buy" rating for Siemens Healthineers after the company's earnings release, with a price target of €60. The healthcare technology manufacturer clearly exceeded expectations for the third consecutive quarter, Julien Dormois wrote in a study released Wednesday. An increased annual forecast reflects strong operating momentum and some tariff relief./rob/tih/nas

  Publication of the original study: July 30, 2025 / 2:03 a.m. / CET

  First distribution of the original study: July 30, 2025 / 2:03 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 30, 2025

  Bernstein maintains Siemens Healthineers at 'Outperform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Siemens Healthineers at "Outperform" following its quarterly results, with a price target of €59. The medical technology group's revenue and margins were unexpectedly strong, wrote Lisa Bedell Clive in an initial response released Wednesday./edh/mis

  Publication of the original study: July 30, 2025 / 6:19 a.m. / UTC

  First distribution of the original study: July 30, 2025 / 6:19 a.m. / UTC

  Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 30, 2025

  UBS leaves Siemens Healthineers at 'Neutral' - Target 50 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €50 following its quarterly results. Sales were slightly better than expected, Graham Doyle wrote in an initial reaction released Wednesday. Adjusted operating profit (EBIT) exceeded the consensus estimate by 8 percent./rob/edh/nas

  Publication of the original study: July 30, 2025 / 5:50 a.m. / GMT

  First distribution of the original study: July 30, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 8, 2025

  Bernstein maintains Siemens Healthineers at 'Outperform'

  NEW YORK (dpa-AFX Analyser) - US analyst Bernstein Research has maintained its rating for Siemens Healthineers at "Outperform" with a price target of €59. The medical technology company's stock is the "Best of Bernstein Pick" for the third quarter, wrote Lisa Bedell Clive in a study released Wednesday. She pointed to the strong success story and considers the share surplus due to a possible further partial sale by the parent company Siemens to be "more than adequately" reflected in the current share price./ck/bek

  Publication of the original study: July 8, 2025 / 9:47 PM / UTC

  First distribution of the original study: July 9, 2025 / 5:00 AM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 7, 2025

  Deutsche Bank lowers target for Siemens Healthineers - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research lowered its price target for Siemens Healthineers from €67 to €62 ahead of the company's earnings release, but maintained its "Buy" rating. In his outlook published on Monday, Falko Friedrichs anticipates a solid third quarter. He expects the annual forecast to be confirmed. However, currency headwinds could cause adjusted earnings per share to tend toward the lower half of the range. However, the company is likely to continue to outperform its competitors./tih/ag

  Publication of the original study: July 7, 2025 / Time not specified in the study / CET

  First distribution of the original study: July 7, 2025 / 8:25 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 7, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Buy" rating on Siemens Healthineers with a price target of €60. Chinese sanctions against medical devices from the EU would have only a minor impact on the European medical technology manufacturers he monitors, Julien Dormois wrote in his industry commentary published on Monday. Their products manufactured in China, as well as imported products whose EU components account for less than 50 percent of the order value, remain unaffected by the Chinese measures. Companies such as Elekta, Philips, and Siemens Healthineers had significant production capacities in China./gl/ag

  Publication of the original study: July 7, 2025 / 7:41 a.m. / ET First distribution of the original study: July 7, 2025 / 7:41 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 26, 2025

  Barclays lowers target for Siemens Healthineers - 'Overweight'

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has lowered its price target for Siemens Healthineers from €62 to €61, but maintained its rating at "Overweight." Growth in the third fiscal quarter is likely to have been in the middle range of the full-year target range, Hassan Al-Wakeel wrote in his outlook for the report published Friday./ag/nas

  Publication of the original study: June 26, 2025 / 8:57 p.m. / GMT

  First distribution of the original study: June 27, 2025 / 4:00 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 26, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Siemens Healthineers ahead of earnings, with a price target of €60. Julien Dormois summarized his thoughts on the company's third fiscal quarter in a report released Thursday. The results should allow the medical technology manufacturer to maintain its conservative guidance for the fiscal year. This means there is still room for improvement in the targets./rob/tih/jha/

  Publication of the original study: June 26, 2025 / 2:00 PM / Time zone not specified in the study

  First distribution of the original study: June 26, 2025 / 2:00 PM / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 19, 2025

  UBS leaves Siemens Healthineers at 'Neutral' - Target 50 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €50. The Bavarian company is among the companies in the European medtech sector where it sees the lowest risk of negative surprises, Graham Doyle wrote in his commentary published Friday following recent discussions./ag/jha/

  Publication of the original study: June 19, 2025 / 2:30 p.m. / GMT

  First distribution of the original study: June 20, 2025 / Time not specified in study / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 6, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Siemens Healthineers with a price target of €60. Julien Dormois wrote this on Friday after a conference in New York with investor relations managers from the Bavarian company. There was some relief regarding the company's China business, which is at least holding steady at a low level. Demand from hospitals remains robust in all regions./rob/ag/ajx

  Publication of the original study: June 6, 2025 / 7:03 a.m. / Time zone not specified in the study

  First distribution of the original study: June 6, 2025 / 7:03 a.m. / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 13, 2025

  UBS lowers target for Siemens Healthineers to 50 euros - 'Neutral'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has lowered its price target for Siemens Healthineers from 53 to 50 euros, but maintained its rating at "neutral." The medical technology group is struggling with numerous external influences but is performing as well as it can, Graham Doyle wrote on Tuesday. A strong second quarter made it possible to reduce this year's profit forecast by only 4.5 percent, despite tariff and currency headwinds. He slightly reduced his estimates up to 2028, primarily due to the impact of foreign exchange./tih/ag

  Publication of the original study: May 13, 2025 / 1:44 PM / GMT

  First distribution of the original study: May 13, 2025 / 1:44 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 8, 2025

  Goldman lowers target for Siemens Healthineers - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Siemens Healthineers from €60 to €56, but maintained its rating at "Neutral." Richard Felton adjusted his estimates on Thursday evening in line with the second-quarter report. He stated that momentum is fundamentally solid, but is suffering from tariff headwinds./ag/jha/

  Publication of the original study: May 8, 2025 / 9:01 PM / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  Barclays lowers target for Siemens Healthineers - 'Overweight'

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has lowered its price target for Siemens Healthineers from €65 to €62, but maintained its rating at "Overweight." Hassan Al-Wakeel sees the quarterly report and the lowered annual targets as a possible cleansing storm. The tariff burden is lower than feared, he wrote on Wednesday evening. He considers his new estimates conservative, while the stock valuation is attractive./ag/ajx

  Publication of the original study: May 7, 2025 / 7:50 PM / GMT

  First distribution of the original study: May 8, 2025 / 4:00 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  Jefferies lowers target for Siemens Healthineers to 60 euros - 'Buy'

  NEW YORK (dpa-AFX Analyst) - Following its quarterly results, analyst Jefferies lowered its price target for Siemens Healthineers from €65 to €60 and maintained its "Buy" rating. The medical technology group's organic revenue growth and operating profit (EBIT) clearly exceeded market expectations, Julien Dormois wrote in a study released Wednesday. However, due to expected tariff burdens, it has reduced its sales and earnings forecasts for the 2024/25 and 2025/26 fiscal years./edh/he

  Publication of the original study: May 7, 2025 / 1:52 PM / ET. First distribution of the original study: May 7, 2025 / 1:52 PM / ET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  Jefferies maintains Siemens Healthineers at 'Buy' - target 65 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Siemens Healthineers with a price target of €65. The Bavarian company clearly exceeded expectations for the second consecutive year, Julien Dormois wrote on Wednesday following the quarterly report. He praised good margin potential across all sectors and sees recovery opportunities in China./rob/ag/bek

  Publication of the original study: May 7, 2025 / 2:09 AM / ET

  First distribution of the original study: May 7, 2025 / 2:09 AM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53 following the company's second-quarter results. Graham Doyle wrote in an initial assessment on Wednesday that revenue and operating profit exceeded consensus estimates. The medical technology manufacturer's outlook implies five percent lower consensus estimates. However, this is likely in line with investors' expectations./rob/bek/gl

  Publication of the original study: May 7, 2025 / 5:39 a.m. / GMT First distribution of the original study: May 7, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 9, 2025

  Jefferies maintains Siemens Healthineers at 'Buy' - target 65 euros

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained a "Buy" rating on Siemens Healthineers with a price target of €65. He doesn't predict a bottom yet, but currently sees the best opportunity in five years to buy structural winners, analyst Raj Jilka wrote in a study released Wednesday. He and his team surveyed over 60 industry research teams in Europe to identify 50 market leaders with durable competitive advantages. These leaders are likely to navigate the high market volatility and generate above-average risk-adjusted returns over the long term. As a global leader in the rapidly growing imaging and radiation therapy markets, Siemens Healthineers is uniquely positioned to create value through strategic partnerships with hospital systems./ck/men

  Publication of the original study: April 9, 2025 / 5:44 a.m. / ET

  First distribution of the original study: April 9, 2025 / 6:00 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 7, 2025

  Bernstein maintains Siemens Healthineers at 'Outperform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Siemens Healthineers at "Outperform" with a price target of €60. With a view to a global trade war, analyst Lisa Bedell Clive examined the impact on the European medical technology sector in an assessment published Monday. Supply chains there are already quite deglobalized, at least with regard to China. However, trade volumes between Europe and the US remain significant. However, certain medical products could be exempt from tariffs./ajx/nas

  Publication of the original study: April 7, 2025 / 5:37 a.m. / UTC

  First distribution of the original study: April 7, 2025 / 5:37 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 31, 2025

  Deutsche Bank Research maintains Siemens Healthineers 'Buy' rating

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Buy" rating on Siemens Healthineers with a price target of €67. The medical technology group is expected to present solid quarterly figures and confirm its targets for the fiscal year, analyst Falko Friedrichs wrote in an outlook published on Monday./gl/edh

  Publication of the original study: March 31, 2025 / 8:05 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 26, 2025

  Jefferies maintains Siemens Healthineers at 'Buy' - target 65 euros

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Buy" rating for Siemens Healthineers ahead of second-quarter results, with a price target of €65. Business in China is likely to improve from now on, wrote analyst Julien Dormois in an outlook published Thursday. The medical technology manufacturer is likely to confirm its cautious statements for the full year./bek/gl

  Publication of the original study: March 26, 2025 / 7:38 p.m. / ET First distribution of the original study: March 26, 2025 / 7:38 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 11, 2025

  Goldman raises target for Siemens Healthineers - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Siemens Healthineers from €58 to €60, but maintained its rating at "neutral." Analyst Richard Felton returns from a visit to China with somewhat more optimism for the European medical technology industry. He wrote this in his commentary published on Tuesday, in which he subsequently raised his estimates slightly./ag/gl

  Publication of the original study: March 11, 2025 / 12:29 / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 10, 2025

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53. US investors are rather apathetic toward European medical technology manufacturers, analyst Graham Doyle wrote in an industry report released Tuesday. The shares are now valued higher than their counterparts in the US, and at the same time, import tariffs are looming from there. Alcon, Siemens Healthineers, and Fresenius were the most frequently discussed companies in discussions with investors./bek/tih

  Publication of the original study: February 10, 2025 / 5:51 PM / GMT

  First distribution of the original study: February 10, 2025 / 5:51 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 7, 2025

  Goldman raises Siemens Healthineers target to 58 euros - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Siemens Healthineers from €56 to €58, but maintained its rating at "Neutral." Analyst Richard Felton adjusted his estimates on Friday evening based on the company's first-quarter results. He justified the slightly higher target price by shifting the valuation period forward./ag/tih

  Publication of the original study: February 7, 2025 / 9:05 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 7, 2025

  Deutsche Bank Research: Siemens Healthineers now a favorite

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has raised its price target for Siemens Healthineers from €62 to €67 and maintained its rating at "Buy." Following the unexpectedly strong results, the shares are now also a "Top Pick," wrote analyst Falko Friedrichs in his commentary on the first fiscal quarter published Friday./ag/gl

  Publication of the original study: February 7, 2025 / 8:07 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 6, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Buy" rating for Siemens Healthineers following its earnings release, with a price target of €60. The medical technology group clearly exceeded expectations in its first fiscal quarter, analyst Julien Dormois wrote in an initial reaction on Thursday. Against this backdrop, the confirmed outlook now appears conservative.

  Publication of the original study: February 6, 2025 / 2:06 a.m. / ET First distribution of the original study: February 6, 2025 / 2:06 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 6, 2025

  Goldman maintains Siemens Healthineers at 'Neutral' - Target 56 euros

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €56. The Bavarian company had a strong start to the year, analyst Richard Felton wrote on Thursday after the company's results. Sales, operating profit, and earnings per share exceeded expectations./ag/gl

  Publication of the original study: February 6, 2025 / 7:18 a.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 6, 2025

  Bernstein maintains Siemens Healthineers at 'Outperform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Siemens Healthineers at "Outperform" following its quarterly results, with a price target of €60. The medical technology group's key figures were stronger than expected, wrote analyst Lisa Bedell Clive in an initial response released Thursday./edh/gl

  Publication of the original study: February 6, 2025 / 7:06 a.m. / UTC First distribution of the original study: February 6, 2025 / 7:06 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 30, 2025

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53. The Bavarian company needs to reduce the risk to its annual targets, wrote analyst Graham Doyle in his commentary on the European medical technology industry's reporting season, published Friday. This is unlikely to be achieved due to the rather less significant first fiscal quarter./ag/mis

  Publication of the original study: January 30, 2025 / 6:04 p.m. / GMT

  First distribution of the original study: January 31, 2025 / Time not specified in the study / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 23, 2025

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53. The diagnostics market in China is currently particularly fragmented compared to the global market, analyst Kavya Deshpande wrote in a study released Friday. He believes this will be a negative development for foreign players, which is particularly counterproductive on the path to a realignment of Siemens Healthineers' diagnostics division./tih/nas

  Publication of the original study: January 23, 2025 / 3:53 PM / GMT

  First distribution of the original study: January 23, 2025 / 3:53 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 16, 2025

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53. Graham Doyle wrote in his analysis published Friday that there is encouraging news in the European medical technology sector following statements from GE Healthcare, which are an early sign of a recovery. Although investor sentiment is turning, he remains cautious due to other countervailing events. Among other things, he referred to the situation in China./tih/ag

  Publication of the original study: January 16, 2025 / 7:47 PM / GMT

  First distribution of the original study: January 16, 2025 / 7:47 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 14, 2025

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53. While the medical technology company's first-quarter figures are likely to be satisfactory, they do not yet eliminate the risks regarding the full year 2025, analyst Graham Doyle wrote in a study released Wednesday. With its revenue estimate for the first quarter, the expert is one percent above the consensus and expects adjusted operating profit (EBIT) two percent above the average estimate./mf/tav

  Publication of the original study: January 14, 2025 / 1:34 PM / GMT

  First distribution of the original study: January 14, 2025 / 1:34 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 13, 2025

  Goldman raises target for Siemens Health to €56 - 'Neutral'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has raised its price target for Siemens Healthineers from €54 to €56 and maintained its rating at "Neutral." Analyst Richard Felton justified the higher price target in a study published Tuesday with exchange rate effects./bek/nas

  Publication of the original study: January 13, 2025 / 9:10 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 13, 2025

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Buy" rating for Siemens Healthineers with a price target of €60. As the first reporting season of 2025 begins, analyst Julien Dormois identified shares of seven companies that he believes could surprise upside. These are: Generali, IAG, Pennon, Pernod, Siemens, Siemens Healthineers, and Volvo, according to an assessment released Monday. He sees potential for disappointment in two stocks: Dassault and Moncler./ajx/he

  Publication of the original study: January 13, 2025 / 8:03 a.m. / ET. First distribution of the original study: January 13, 2025 / 11:00 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 19, 2024

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for Siemens Healthineers with a price target of €60. A sluggish start to the new 2024/25 fiscal year should come as no surprise, wrote analyst Julien Dormois in his outlook for the first-quarter report on February 6, published Thursday. The prudently set annual targets nevertheless leave room for improvement should business in China normalize./ag/ck

  Publication of the original study: December 19, 2024 / 2:50 a.m. / ET

  First distribution of the original study: December 19, 2024 / 2:50 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 8, 2024

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained its rating for Siemens Healthineers at "Buy" with a price target of 60 euros at the annual radiology conference RSNA. Three years after the market launch of the world's first PCCT scanner, the medical technology group is taking the next major step in transforming the computed tomography market and positioning the groundbreaking technology in the lower price segments, wrote analyst Julien Dormois in his commentary published on Monday./edh/ag

  Publication of the original study: December 8, 2024 / 4:41 p.m. / ET

  First distribution of the original study: December 8, 2024 / 7:01 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 2, 2024

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53. The Erlangen-based company has cemented its leadership in photon-counting computed tomography (PCCT) by expanding its pipeline from one to three devices, analyst Graham Doyle wrote in a report released Monday. They can now serve different target groups and budgets./ag/nas

  Publication of the original study: December 2, 2024 / 11:22 AM / GMT

  First distribution of the original study: December 2, 2024 / 11:22 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 26, 2024

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €53

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €53. Although European medical technology stocks have underperformed the overall market this year, analyst Graham Doyle remains skeptical about the sector in general. His 2025 revenue and earnings forecasts for 10 of the 17 sector stocks he covers are below consensus estimates, he wrote in an industry commentary released Tuesday. /edh/ag

  Publication of the original study: November 26, 2024 / 4:08 a.m. / GMT

  First distribution of the original study: November 26, 2024 / 4:08 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 20, 2024

  Jefferies maintains Siemens Healthineers 'Buy' - target 60 euros

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for Siemens Healthineers with a price target of €60. The Chinese business remains a "wildcard," wrote analyst Julien Dormois in his commentary on a roadshow in London on Thursday. At least the revenue decline slowed in the fourth fiscal quarter. The company's targets for 2025 have boosted sentiment, and medium-term ambitions remain intact./ag/edh

  Publication of the original study: November 20, 2024 / 7:28 PM / ET

  First distribution of the original study: November 20, 2024 / 8:00 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 8, 2024

  Deutsche Bank raises target for Siemens Healthineers - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has raised its price target for Siemens Healthineers from €60 to €62 and maintained its "Buy" rating. After a series of disappointing quarterly reports, the medical technology group has fortunately started the new fiscal year with more conservative targets, wrote analyst Falko Friedrichs in a review published Friday. The latest quarterly figures underscored the undisputed global leadership in the structural growth areas of radiographic imaging and cancer treatments.

  Publication of the original study: November 8, 2024 / 8:30 a.m. / CET. First distribution of the original study: Date not specified in study / Time not specified in study / CET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 7, 2024

  Deutsche Bank maintains 'Buy' rating on Siemens Healthineers

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Siemens Healthineers following its quarterly results, with a price target of €60. The medical technology group's key performance indicators were strong, but its annual outlook is conservative, wrote analyst Falko Friedrichs in a study published Thursday./edh/tih

  Publication of the original study: November 7, 2024 / Time not specified in study / CET

  First distribution of the original study: November 7, 2024 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  Jefferies raises target for Siemens Healthineers to 60 euros - 'Buy'

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies raised its price target for Siemens Healthineers from €58 to €60 and maintained its rating at "Buy." The fiscal year results were impressive, wrote analyst Julien Dormois on Wednesday after the report. The book-to-bill ratio was strong./ag/gl

  Publication of the original study: November 6, 2024 / 3:52 p.m. / ET First distribution of the original study: November 6, 2024 / 7:00 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  UBS raises target for Siemens Healthineers to 53 euros - 'Neutral'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has raised its price target for Siemens Healthineers from 51 to 53 euros and maintained its rating at "Neutral." The medical technology group's fourth fiscal quarter was strong, wrote analyst Graham Doyle in a report released Thursday. The positive reception of the figures was also due to the fact that consensus had expected mixed results. The caution regarding the company's forecast for 2024/25 is prudent. It appears achievable even in the current uncertain environment in China./ck/gl

  Publication of the original study: November 6, 2024 / 7:12 PM / GMT. First distribution of the original study: November 6, 2024 / 7:12 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  Goldman maintains Siemens Healthineers at 'Neutral' - Target 54 euros

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €54. Analyst Richard Felton adjusted his estimates on Wednesday evening based on the quarterly report, currency developments, and current management signals. Slightly lower expectations would be offset by shifting the valuation basis further into the future./ag/ck

  Publication of the original study: November 6, 2024 / 9:15 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  Goldman maintains Siemens Healthineers at 'Neutral' - Target 54 euros

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €54. The end of the fiscal year was solid, wrote analyst Richard Felton on Wednesday morning after the company's results. However, the targets for 2025 are below expectations./ag/gl

  Publication of the original study: November 6, 2024 / 7:06 a.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  UBS maintains 'Neutral' rating on Siemens Healthineers - Target: €51

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Siemens Healthineers at "Neutral" with a price target of €51. Analyst Graham Doyle wrote on Wednesday morning after the company's results. The company's profit target for 2025 is below expectations. However, some might be happy with a more conservative approach./ag/gl

  Publication of the original study: November 6, 2024 / 6:38 a.m. / GMT First distribution of the original study: November 6, 2024 / 6:38 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 30, 2024

  Deutsche Bank Research maintains Siemens Healthineers 'Buy' rating

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Siemens Healthineers at "Buy" with a price target of €60. Given Philips' continued weakness in China, investors should also prepare for disappointment with its German competitor, wrote analyst Falko Friedrichs in his commentary published Wednesday, with a view to the upcoming quarterly report in early November./ag/nas

  Publication of the original study: October 30, 2024 / Time not specified in study / CET

  First distribution of the original study: October 30, 2024 / 08:17 / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 25, 2024

  UBS lowers Siemens Healthineers to 'Neutral' - target at 51 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has downgraded Siemens Healthineers from "Buy" to "Neutral" and lowered its price target from €56 to €51. In the short term, the medical technology group is likely to disappoint in the crucial Chinese market, Graham Doyle wrote in his analysis published Thursday. He says his growth forecast for the coming year is below consensus. However, he also expects Chinese upstarts in the imaging business to erode market share in the medium term. He therefore reduced his expectations of his Western counterparts./ag/gl

  Publication of the original study: September 25, 2024 / 10:10 PM / GMT. First distribution of the original study: September 25, 2024 / 10:10 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.